Florida Pharmacist Convicted of Flooding Communities with Over 335,000 Oxycodone Pills

How a Florida Pharmacist Turned Locked Doors and Cash Payments Into a Pill Mill

A federal jury in Miami convicted 60-year-old pharmacist Olushola Yusuf on charges of conspiracy to illegally distribute controlled substances and five counts of illegal drug distribution. Over several years, Yusuf used her two South Florida pharmacies—Boots LLC (Margate) and Chans Pharmacy Plus (Pembroke Pines)—to dispense more than 335,000 oxycodone 30mg tablets, the maximum potency available. The high-dose pills are normally reserved for severe cancer pain or traumatic injuries, yet Yusuf provided them to virtually any customer who paid in cash, often at ten times the typical cost.

Evidence showed that customers drove from across the state to fill prescriptions no other pharmacy would touch. Some spent as much as $1,000 a month. Drug dealers collected pills on behalf of dozens of absent “patients.” Despite repeated warnings from her own employees and the DEA, Yusuf kept the pharmacy doors locked during business hours, instructing staff to admit only certain regulars. The cash-only, high-price model, combined with the locked doors and long-distance clientele, painted a picture of a full-scale pill mill operating behind a pharmacy license.

Red Flags and Repeated Warnings: Why Yusuf’s Operation Kept Running

The Red Flags Yusuf Ignored

Prosecutors laid out a pattern that would have alarmed any legitimate pharmacist: customers paying extreme cash markups for maximum-strength oxycodone, individuals collecting prescriptions for dozens of people not present, and a steady stream of out-of-town patients. Yusuf’s own employees testified that they warned her about the dangers. The DEA also flagged the operation, yet she continued. Locking the doors and screening customers was itself a deliberate tactic, not an oversight.

Why the DEA and DOJ Joined Forces

The case reflects heightened coordination between the DEA and the Justice Department’s newly created Fraud Division, which also found evidence that Yusuf bought patient data to generate sham medical orders and target Medicare and Medicaid beneficiaries. The fraud angle adds a healthcare-finance dimension to what might otherwise look like a straightforward drug trafficking case. The DOJ explicitly linked the prosecution to the President’s Task Force to Eliminate Fraud, signaling that pharmacy-related opioid cases will increasingly be scrutinized for both drug diversion and false claims on federal programs.

The Sentencing and Its Deterrent Signal

Yusuf faces up to 20 years per count when she is sentenced on October 14, 2026. Her co-defendant, Saman Gimenez, already pleaded guilty and awaits sentencing the same month. U.S. Attorney Jason A. Reding Quiñones described the conviction as a message that drug dealing from behind a counter will be treated no differently than street-level trafficking. For an industry still wrestling with the legacy of the opioid epidemic, the verdict reinforces that compliance must be more than paperwork—it requires acting on red flags when they appear.

Three Immediate Steps for Pharmacy Operators After the Yusuf Conviction

For pharmacy owners and compliance officers, the Yusuf trial highlights specific operational benchmarks to review immediately:

• Scrutinize cash purchases of high-dose controlled substances. Yusuf’s customers paid roughly ten times the going rate in cash. Any pattern where cash transactions make up a disproportionate share of Schedule II sales demands a documented justification and, if unsupported, a halt.
• Revisit your policy on remote-volume prescription fills. Witnesses described customers collecting for dozens of absent individuals—an obvious red flag that should trigger mandatory pharmacist intervention, prescription verification, and, if warranted, a refusal to fill.
• Don’t discount internal warnings. Yusuf’s employees repeatedly advised her of the risks. Formalize a process so that staff concerns about questionable dispensing reach an independent compliance function, not just the owner, and are acted upon before regulators issue a formal warning.

With the DOJ’s Fraud Division now operational and explicitly targeting healthcare fraud tied to controlled substances, pharmacies that treat these signals as mere suggestions risk criminal exposure, not just regulatory fines.